scispace - formally typeset
Open AccessJournal ArticleDOI

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial†

Chloe Orkin, +9 more
- 01 Jan 2013 - 
- Vol. 14, Iss: 1, pp 49-59
Reads0
Chats0
TLDR
The final analysis of once‐daily darunavir/ritonavir (DRV/r) vs. lopinavir/drive (LPV/ r) in treatment‐naïve HIV‐1‐infected adults in treatment-naïve adults is presented.
Abstract: 
Objective This paper presents the final analysis of once-daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment-naive HIV-1-infected adults. Methods ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects; NCT00258557) was a randomized, open-label, phase-III, 192-week trial. Patients were stratified by baseline HIV-1 RNA and CD4 count, and randomized to once-daily DRV/r 800/100 mg or LPV/r 800/200 mg total daily dose (either once or twice daily) plus tenofovir/emtricitabine. Results Of 689 randomized patients receiving treatment (DRV/r: 343; LPV/r: 346), 85 and 114 patients in the DRV/r and LPV/r arms, respectively, had discontinued by week 192. Noninferiority was shown in the primary endpoint of virological response (HIV-1 RNA Conclusion Over 192 weeks, once-daily DRV/r was noninferior and statistically superior in virological response to LPV/r, with a more favourable gastrointestinal profile, demonstrating its suitability for long-term use in treatment-naive patients.

read more

Citations
More filters
Journal ArticleDOI

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

François Raffi, +18 more
- 29 Nov 2014 - 
TL;DR: The 96 week NtRTI-sparing regimen was non-inferior to standard treatment and represents a treatment option for patients with CD4 cell counts higher than 200 cells per μL and the frequency of serious or treatment-modifying adverse events were similar.
Journal ArticleDOI

Antiretroviral Therapy: Current Drugs

Alice K. Pau, +1 more
- 01 Sep 2014 - 
TL;DR: The history of antiretroviral drug development is reviewed and the clinical pharmacology, efficacy, and toxicities of the antireTroviral agents most commonly used in clinical practice to date are discussed.
Journal ArticleDOI

Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

Steve Kanters, +10 more
- 01 Nov 2016 - 
TL;DR: A systematic review and network meta-analysis comparing recommended antiretroviral regimens in treatment-naive adults and adolescents with HIV found that low event rates limited the quality of evidence with regard to mortality and AIDS defining illnesses.
Journal ArticleDOI

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

Lene Ryom, +14 more
- 01 Jun 2018 - 
TL;DR: Cumulative use of ritonavir-boosted darunavir, but not of rittonavir -boosted atazanvir, is associated with progressively increasing risk of cardiovascular disease.
Journal ArticleDOI

Lack of antiviral activity of darunavir against SARS-CoV-2.

Sandra De Meyer, +7 more
- 01 Aug 2020 - 
TL;DR: The data do not support the use of DRV for treatment of COVID-19, and the in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed.
References
More filters
Journal ArticleDOI

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

Anthony S. Fauci, +46 more
- 24 Apr 1998 - 
TL;DR: These Guidelines were developed by the Panel* on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation.

Update of the Drug Resistance Mutations in HIV-1.

Victoria A. Johnson, +7 more
TL;DR: The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.
Journal ArticleDOI

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

Jean-Michel Molina, +11 more
- 23 Aug 2008 - 
TL;DR: In treatment-naive patients, atazanavir/ritonavir once-daily demonstrated similar antiviral efficacy to lopinavIR/rit onavir twice-daily, with less gastrointestinal toxicity but with a higher rate of hyperbilirubinaemia.
Journal ArticleDOI

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, +16 more
- 07 Apr 2007 - 
TL;DR: Efficacy responses with darunavir-ritonavir 600/100 mg twice daily plus optimised background regimen were greater than those with control PI and were sustained to at least week 48, with favourable safety and tolerability in treatment-experienced patients.
Journal ArticleDOI

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Roberto Ortiz, +11 more
- 31 Jul 2008 - 
TL;DR: DRV/r 800/100 mg qd was non-inferior to LPV/ r 800/200 mg at 48 weeks, with a more favorable safety profile, and offers a new effective and well tolerated once-daily, first-line treatment option for treatment-naive patients.
Related Papers (5)

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Roberto Ortiz, +11 more
- 31 Jul 2008 - 

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, +16 more
- 07 Apr 2007 - 

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Edwin DeJesus, +11 more
- 30 Jun 2012 - 

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents

Anthony S. Fauci, +46 more
- 24 Apr 1998 - 

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Bonaventura Clotet, +13 more
- 28 Jun 2014 -